Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System
- 460 Downloads
Background and Objectives
Trastuzumab emtansine (T-DM1, KADCYLA®) is an antibody–drug conjugate comprised of the cytotoxic agent DM1 and trastuzumab (HERCEPTIN®). The safety profile of T-DM1 in human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane was investigated in the phase III EMILIA trial. The trial demonstrated clinically and statistically meaningful differences in the safety profile between T-DM1 and capecitabine plus lapatinib (CAP + LAP). The objective of this study was to estimate the costs of managing treatment-related grade ≥3 adverse events (AEs) that occurred in ≥2 % of patients and grade 2 AEs that occurred in ≥5 % of patients taking T-DM1 compared with patients taking CAP + LAP based on the EMILIA trial, from the perspective of Canadian public payers.
An Excel-based model was utilized to estimate the relevant costs. Clinical data were obtained from the EMILIA trial. Cost information was obtained from the literature, clinical experts, and standard cost sources. The analysis was conducted from the Canadian public-payer perspective and reported in 2014 Canadian dollars (CAD).
The management of included treatment-related AEs resulted in higher estimated per-patient costs of CAD6901 for CAP + LAP versus CAD3380 for T-DM1, resulting in savings of CAD3521.
From a Canadian perspective, this analysis demonstrated that utilizing T-DM1 for the management of HER2-positive metastatic breast cancer results in substantial savings to the public health-care system when considering the costs of treatment-related AEs, due to fewer amount of toxicities compared with CAP + LAP. Results of various sensitivity analyses investigating changes in number and costs of AEs confirmed the findings; however, the magnitude of cost savings varied. Further analyses are necessary to determine whether these cost savings would occur in other countries and health-care systems.
KeywordsTrastuzumab Metastatic Breast Cancer Capecitabine Lapatinib Pertuzumab
Compliance with Ethical Standards
Source of funding
F. Hoffmann-La Roche AG., Basel, Switzerland.
Conflicts of interest
Charles Piwko—Consultant for Hoffmann-La Roche. Catherine Prady—Clinical expert—was reimbursed for the time spent on the study and manuscript. Simon Yunger—Employee of Hoffmann-La Roche. Erika Pollex—was an employee of Hoffmann-La Roche at the time of preparing the manuscript. Aurelie Moser—Employee of Hoffmann-La Roche.
The EMILIA study (Verma et al 2012, N Engl J Med, from which data were taken for this analysis) was conducted in accordance with the International Conference on Harmonization Good Clinical Practice standards and the Declaration of Helsinki. Patients provided written informed consent; the study was approved by the relevant institutional review board or independent ethics committee.
- 1.Worldwide breast cancer. Breast Cancer Statistis Worldwide. http://www.worldwidebreastcancercom/learn/breast-cancer-statistics-worldwide/;accessed Accessed 25 Apr 2014.
- 3.Canadian Cancer Statistics 2014. Special topic; Skin cancers, at http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2014–EN.pdf.
- 4.SEER Stat Fact Sheets: Breast Cancer. NCI Surveillance and Epidemiology Results (SEER) 2012, at http://www.seer.cancer.gov.
- 12.Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.PubMedCrossRefGoogle Scholar
- 14.Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.PubMedCrossRefGoogle Scholar
- 22.Hoffmann-La Roche Limited. KADCYLA Product Monograph. 2014.Google Scholar
- 23.Hoffman La-Roche. Data on File.Google Scholar
- 24.Bank of Canada. http://www.bankofcanada.ca/en/rates/inflation_calc.html. 2009.
- 25.Ontario Health Insurance. Schedule of Benefits and Fees. 2012.Google Scholar
- 26.Ontario Drug Benefit Program. Formulary.Google Scholar
- 27.Kralj B, Kantarevic J. Primary care model enrolment and hospital length of stay in Ontario: patient rostering associated with reduced length of stay, significant health system savings. Ontario Medical Review 2012.Google Scholar
- 28.Survey with Canadian clinical experts to determine cost of treatment-related adverse events. Data on file 2013.Google Scholar
- 29.Dranitsaris G. A retrospective cohort study to measure the cost of diarrhea in patients with colorectal cancer receiving chemotherapy. Annual Meeting of the American Society of Clinical Oncology; 2004; New Orleans, LA.Google Scholar
- 32.Bouwmans C, Janssen J, Huijgens P, Uyl-de Groot C. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. J Med Econ. 2009;12:164–9.PubMedCrossRefGoogle Scholar
- 35.Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19:131–40.PubMedCrossRefGoogle Scholar